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Introduction
Juvenile dermatomyositis patients may experience persis-
tent weakness, loss of bone mass, and skeletal muscle atro-
phy as a long-term result of drug treatment and/or disease
itself. In this regard, efforts to develop new therapeutic
strategies able to attenuate these adverse outcomes have
been considered of clinical relevance. It has been sug-
gested that creatine supplementation could be safe, effec-
tive and inexpensive for treating idiopathic inflammatory
myopathies, but no pediatric study has been conducted
so far.
Objectives
To examine the safety and efficacy of creatine supple-
mentation in JDM patients
Methods
JDM patients received placebo or creatine supplementa-
tion (0.1 g/kg/d) in a randomized, crossover, double-
blind, repeated-measures design. Subjects were assessed
at baseline and after 12 weeks, with 8-week washout per-
iod. Primary outcome was muscle function. Secondary
outcomes included body composition, bone mineral den-
sity, biochemical markers of bone remodeling, inflamma-
tory cytokines, aerobic conditioning, health-related
quality of life, and disease-related parameters, dietary
intake and muscle phosphorylcreatine (PCR) content.
Safety was assessed by laboratory parameters and kidney
function
Results
Intramuscular PCR content was not significantly differ-
ent between creatine and placebo before or after the
intervention (Creatine - Pre: 21.4 ± 5.3, Post: 20.6 ± 2.7,
delta score = -0.3 ± 2.5 mmol/kg wet muscle, ES =
-0.15; Placebo - Pre: 20.4 ± 3.7, Post: 20.7 ± 3.6, delta
score = -0.1 ± 4.2 mmol/kg wet muscle, ES = -0.15; 95%
CI for delta score = -2.8 ± 2.4, p = 0.45 for interaction
between creatine and placebo). No significant changes
between placebo and creatine for muscle function and
aerobic conditioning, body composition, bone mineral
density, and quality of life were seen, probably due to
the lack of change in intramuscular PCR content. Kid-
ney function was not changed after creatine supplemen-
tation and no side effects were noticed.
Conclusion
A 12-week creatine supplementation protocol is well tol-
erable and free of adverse effects but did not affect intra-
muscular PCR, muscle function, body composition, bone
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